Francis Medical Expands Commercial Use of Vanquish System for Prostate Tissue Ablation

Event summary

  • Francis Medical's Vanquish® Water Vapor Ablation System completed first commercial procedures in San Antonio, Texas, led by Dr. Naveen Kella.
  • 91% of VAPOR 2 study patients showed negative biopsy results at six months post-procedure.
  • No device-related serious adverse events reported, with low rates of urinary incontinence and erectile dysfunction.
  • Vanquish System cleared for thermal ablation of prostate tissue, but not yet evaluated by FDA for prostate cancer treatment.

The big picture

Francis Medical's expansion of commercial Vanquish procedures marks a shift from clinical investigation to real-world patient care, aligning with broader trends toward minimally invasive urological cancer treatments. The company's focus on balancing efficacy with quality-of-life outcomes positions it within a competitive landscape where traditional therapies often come with significant side effects. The success of this commercial rollout could influence future FDA evaluations and market penetration strategies.

What we're watching

Regulatory Pathway
The pace at which Francis Medical can secure FDA pre-market approval (PMA) for expanded indications, given the ongoing five-year follow-up of the VAPOR 2 study.
Market Adoption
Whether the positive real-world outcomes will accelerate commercial adoption beyond San Antonio, particularly among urologists familiar with the VAPOR 2 study.
Competitive Positioning
How Francis Medical differentiates Vanquish from existing prostate cancer treatments, emphasizing quality-of-life benefits while awaiting long-term efficacy data.

Related topics

Medical Devices